Abstract P5-13-01: Uptake of breast cancer chemoprevention among high-risk women and those with ductal carcinoma in situ.

@inproceedings{Sivasubramanian2013AbstractPU,
  title={Abstract P5-13-01: Uptake of breast cancer chemoprevention among high-risk women and those with ductal carcinoma in situ.},
  author={Ps Sivasubramanian and Laura L. Reimers and Heather Greenlee and Mary Beth Terry and Dawn L. Hershman and Matthew Maurer and Kevin Kalinsky and Danielle Awad and Tong Xiao and R Eunice Sandoval and Mariano J. Alvarez and Antonio Quirarte and Julie D. Campbell and Katherine D Crew},
  year={2013}
}
Background: Chemoprevention with antiestrogens, such as tamoxifen, raloxifene, and aromatase inhibitors (AIs), reduces breast cancer incidence in high-risk women. However, uptake has been poor in the prevention setting. We examined demographic and clinical factors that influenced chemoprevention uptake in women with an elevated Gail risk score (≥1.67%), lobular/ductal carcinoma in situ (LCIS/DCIS), and/or BRCA mutation carriers. Methods: We enrolled women prospectively without a diagnosis of… CONTINUE READING